<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "81: carefully", fill: "#967bb6"},
{source: "81: carefully", target: "81: investment", fill: "#967bb6"},
{source: "81: investment", target: "81: Company ", fill: "#967bb6"},
{source: "81: Company ", target: "81: forwardlooking", fill: "#967bb6"},
{source: "81: carefully", target: "85: inability", fill: "#002395"},
{source: "85: inability", target: "85: regulatory", fill: "#002395"},
{source: "85: regulatory", target: "85: expenditures", fill: "#002395"},
{source: "85: expenditures", target: "85: competitive", fill: "#002395"},
{source: "85: competitive", target: "85: developments", fill: "#002395"},
{source: "85: inability", target: "93: As of March ", fill: "#e9d66b"},
{source: "93: As of March ", target: "93: entered into", fill: "#e9d66b"},
{source: "93: entered into", target: "93: agreements", fill: "#e9d66b"},
{source: "93: agreements", target: "93: with respect", fill: "#e9d66b"},
{source: "93: with respect", target: "93: marketing upon", fill: "#e9d66b"},
{source: "93: marketing upon", target: "93: development", fill: "#e9d66b"},
{source: "93: As of March ", target: "94: agreement", fill: "#f0fff0"},
{source: "94: agreement", target: "94: commercially", fill: "#f0fff0"},
{source: "94: commercially", target: "94: codevelop", fill: "#f0fff0"},
{source: "94: codevelop", target: "94: regulatory", fill: "#f0fff0"},
{source: "94: regulatory", target: "94: manufacture", fill: "#f0fff0"},
{source: "94: manufacture", target: "94: marketing partner", fill: "#f0fff0"},
{source: "94: marketing partner", target: "94: distribution", fill: "#f0fff0"},
{source: "94: agreement", target: "101: pilot bioequivalence", fill: "#fddde6"},
{source: "101: pilot bioequivalence", target: "112: regulatory", fill: "#1560bd"},
{source: "112: regulatory", target: "112: commercial sale", fill: "#1560bd"},
{source: "112: commercial sale", target: "112: potential products", fill: "#1560bd"},
{source: "112: potential products", target: "112: clinical trials", fill: "#1560bd"},
{source: "112: clinical trials", target: "112: demonstrate", fill: "#1560bd"},
{source: "112: regulatory", target: "129: special risks", fill: "#fbec5d"},
{source: "129: special risks", target: "129: possibility", fill: "#fbec5d"},
{source: "129: possibility", target: "129: disruption due", fill: "#fbec5d"},
{source: "129: disruption due", target: "129: transportation", fill: "#fbec5d"},
{source: "129: transportation", target: "129: communication problems", fill: "#fbec5d"},
{source: "129: communication problems", target: "129: instability", fill: "#fbec5d"},
{source: "129: instability", target: "129: governments", fill: "#fbec5d"},
{source: "129: governments", target: "129: PAGE ", fill: "#fbec5d"},
{source: "129: PAGE ", target: "129: interim price volatility", fill: "#fbec5d"},
{source: "129: interim price volatility", target: "129: based on labor unrest", fill: "#fbec5d"},
{source: "129: based on labor unrest", target: "129: restrictions", fill: "#fbec5d"},
{source: "129: restrictions", target: "129: fluctuations", fill: "#fbec5d"},
{source: "129: fluctuations", target: "129: currency exchange rates", fill: "#fbec5d"},
{source: "129: currency exchange rates", target: "129: uncertainty", fill: "#fbec5d"},
{source: "129: uncertainty", target: "129: legal system", fill: "#fbec5d"},
{source: "129: legal system", target: "129: enforcement", fill: "#fbec5d"},
{source: "129: special risks", target: "134: Company ", fill: "#c46210"},
{source: "134: Company ", target: "134: Common Stock ", fill: "#c46210"},
{source: "134: Company ", target: "START_HERE", fill: "#c46210"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Oil and Gas Storage and Transportation</td>
    </tr>
    <tr>
      <td>Oil and Gas Refining and Marketing and Transportation</td>
    </tr>
    <tr>
      <td>Transportation</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Economic</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Pessimistic comment</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Promise policy support</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Reject</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Covert monitoring</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Company">Company</a></td>
      <td>A company, abbreviated as co., is a legal entity representing an association of people, whether natural, legal or a mixture of both, with a specific objective. Company members share a common purpose and unite to achieve specific, declared goals.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Amazon_(company)">Amazon (company)</a></td>
      <td>Amazon.com, Inc. ( AM-ə-zon) is an American multinational technology company which focuses on e-commerce, cloud computing, digital streaming, and artificial intelligence.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Public_company">Public company</a></td>
      <td>A public company, publicly traded company, publicly held company, publicly listed company, or public limited company is a company whose ownership is organized via shares of stock which are intended to be freely traded on a stock exchange or in over-the-counter markets. A public (publicly traded) company can be listed on a stock exchange (listed company), which facilitates the trade of shares, or not (unlisted public company).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Privately_held_company">Privately held company</a></td>
      <td>A privately held company or private company is a company which does not offer or trade its company stock (shares) to the general public on the stock market exchanges, but rather the company's stock is offered, owned and traded or exchanged privately or over-the-counter. In the case of a close corporation, there are a relatively small number of shareholders or company members.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/East_India_Company">East India Company</a></td>
      <td>The East India Company (EIC) was an English, and later British, joint-stock company founded in 1600. It was formed to trade in the Indian Ocean region, initially with the East Indies (the Indian subcontinent and Southeast Asia), and later with East Asia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Subsidiary">Subsidiary</a></td>
      <td>A subsidiary, subsidiary company or daughter company is a company owned or controlled by another company, which is called the parent company or holding company. Two or more subsidiaries that belong to the same parent company are called sister companies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Walt_Disney_Company">The Walt Disney Company</a></td>
      <td>The Walt Disney Company, commonly known as Disney (), is an American multinational mass media and entertainment conglomerate headquartered at the Walt Disney Studios complex in Burbank, California.\nDisney was originally founded on October 16, 1923, by brothers Walt and Roy O. Disney as the Disney Brothers Cartoon Studio; it also operated under the names the Walt Disney Studio and Walt Disney Productions before changing its name to the Walt Disney Company in 1986.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Minsk_agreements">Minsk agreements</a></td>
      <td>The Minsk agreements were a series of international agreements which sought to end the war in the Donbas region of Ukraine. The first, known as the Minsk Protocol, was drafted in 2014 by the Trilateral Contact Group on Ukraine, consisting of Ukraine, Russia, and the Organization for Security and Co-operation in Europe (OSCE), with mediation by the leaders of France and Germany in the so-called Normandy Format.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Non-disclosure_agreement">Non-disclosure agreement</a></td>
      <td>A non-disclosure agreement (NDA), also known as a confidentiality agreement (CA), confidential disclosure agreement (CDA), proprietary information agreement (PIA), secrecy agreement (SA), or non-disparagement agreement, is a legal contract or part of a contract between at least two parties that outlines confidential material, knowledge, or information that the parties wish to share with one another for certain purposes, but wish to restrict access to. Doctor–patient confidentiality (physician–patient privilege), attorney–client privilege, priest–penitent privilege and bank–client confidentiality agreements are examples of NDAs, which are often not enshrined in a written contract between the parties.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Good_Friday_Agreement">Good Friday Agreement</a></td>
      <td>The Good Friday Agreement (GFA), or Belfast Agreement (Irish: Comhaontú Aoine an Chéasta or Comhaontú Bhéal Feirste; Ulster-Scots: Guid Friday Greeance or Bilfawst Greeance), is a pair of agreements signed on 10 April 1998 that ended most of the violence of the Troubles, a political conflict in Northern Ireland that had ensued since the late 1960s. It was a major development in the Northern Ireland peace process of the 1990s.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development_hell">Development hell</a></td>
      <td>Development hell, development purgatory, and development limbo are media and software industry jargon for a project, concept, or idea that remains in development for an especially long time, often moving between different crews, scripts, game engines, or studios before it progresses to production, if it ever does. Projects in development hell are usually not released until development has reached a satisfying state worthy of being released, ready for production.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Personal_development">Personal development</a></td>
      <td>Personal development or self improvement consists of activities that develop a person's capabilities and potential, build human capital, facilitate employability, and enhance quality of life and the realization of dreams and aspirations. Personal development may take place over the course of an individual's entire lifespan and is not limited to one stage of a person's life.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trial">Clinical trial</a></td>
      <td>Clinical trials are experiments or observations done in clinical research. Such prospective biomedical or behavioral research studies on human participants are designed to answer specific questions about biomedical or behavioral interventions, including new treatments (such as novel vaccines, drugs, dietary choices, dietary supplements, and medical devices) and known interventions that warrant further study and comparison.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Phases_of_clinical_research">Phases of clinical research</a></td>
      <td>The phases of clinical research are the stages in which scientists conduct experiments with a health intervention to obtain sufficient evidence for a process considered effective as a medical treatment. For drug development, the clinical phases start with testing for safety in a few human subjects, then expand to many study participants (potentially tens of thousands) to determine if the treatment is effective.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Adaptive_clinical_trial">Adaptive clinical trial</a></td>
      <td>An adaptive clinical trial is a dynamic clinical trial that evaluates a medical device or treatment by observing participant outcomes (and possibly other measures, such as side-effects) on a prescribed schedule, and, uniquely, modifying parameters of the trial protocol in accord with those observations. This is in contrast to traditional randomized clinical trials (RCTs) that are static in their protocol and do not modify any parameters until the trial is completed.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Randomized_controlled_trial">Randomized controlled trial</a></td>
      <td>A randomized controlled trial (or randomized control trial; RCT) is a form of scientific experiment used to control factors not under direct experimental control. Examples of RCTs are clinical trials that compare the effects of drugs, surgical techniques, medical devices, diagnostic procedures or other medical treatments.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pragmatic_clinical_trial">Pragmatic clinical trial</a></td>
      <td>A pragmatic clinical trial (PCT), sometimes called a practical clinical trial (PCT), is a clinical trial that focuses on correlation between treatments and outcomes in real-world health system practice rather than focusing on proving causative explanations for outcomes, which requires extensive deconfounding with inclusion and exclusion criteria so strict that they risk rendering the trial results irrelevant to much of real-world practice.\n\n\n== Examples ==\nA typical example is that an anti-diabetic medication in the real world will often be used in people with (latent or apparent) diabetes-induced kidney problems, but if a study of its efficacy and safety excluded some subsets of people with kidney problems (to escape confounding), the study's results may not reflect well what will actually happen in broad practice.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Monitoring_in_clinical_trials">Monitoring in clinical trials</a></td>
      <td>Clinical monitoring is the oversight and administrative efforts that monitor a participant's health and efficacy of the treatment during a clinical trial. Both independent and government-run grant-funding agencies, such as the National Institutes of Health (NIH) and the World Health Organization (WHO), require data and safety monitoring protocols for Phase I and II clinical trials conforming to their standards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_Trials_Directive">Clinical Trials Directive</a></td>
      <td>The Clinical Trials Directive (Officially Directive 2001/20/EC of 4 April 2001, of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use) is a European Union directive that aimed at facilitating the internal market in medicinal products within the European Union, while at the same time maintaining an appropriate level of protection for public health. It seeks to simplify and harmonise the administrative provisions governing clinical trials in the European Community, by establishing a clear, transparent procedure.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_in_India">Clinical trials in India</a></td>
      <td>Clinical trials in India refers to clinical research in India in which researchers test drugs and other treatments on research participants. NDCTR 2019 and section 3.7.1 to 3.7.3 of ICMR guidelines requires that all researchers conducting a clinical trial must publicly document it in the Clinical Trials Registry - India.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Clinical_trials_on_Ayurveda">Clinical trials on Ayurveda</a></td>
      <td>Clinical trials on Ayurveda refers to any clinical trials done on Ayurvedic treatment. Ayurveda is a traditional medicine system in India and like other cultural medical practices includes both conventional medicine and also complementary and alternative medicine.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>ELITE PHARMACEUTICALS INC /DE/    Item 1A      <font color="blue">Risk Factors</font></td>
    </tr>
    <tr>
      <td>11  ITEM 1A          RISK FACTORS             In addition to the other  information  contained  in this  report,  the  following  risk  factors  should  be  considered   <font color="blue">carefully</font>  in  evaluating  an  <font color="blue">investment</font>  in  the  <font color="blue">Company  </font>and in  analyzing  the  Companyapstas  forward-looking  statements</td>
    </tr>
    <tr>
      <td>WE HAVE A  RELATIVELY  LIMITED  OPERATING  HISTORY,  WHICH MAKES IT DIFFICULT TO  EVALUATE OUR FUTURE PROSPECTS             Although we have been in  operation  since 1990,  we have a  <font color="blue">relatively</font>  <font color="blue">in<font color="blue">significant</font></font>  operating  history and limited  <font color="blue">financial data upon which</font> you may  evaluate our business and prospects</td>
    </tr>
    <tr>
      <td>As a result,  our  potential  for  future  <font color="blue">profitability</font>  must be  considered  in light of the  risks,  <font color="blue">uncertainties</font>,  expenses  and  <font color="blue"><font color="blue">difficult</font>ies</font>  <font color="blue">frequently encountered by companies</font> that are attempting to move <font color="blue">into new markets</font>  and  continuing  to <font color="blue">innovate with new</font> and unproven  <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Some of these  risks relate to our potential <font color="blue">inability</font> to:             o        develop <font color="blue">new products</font>;             o        obtain <font color="blue">regulatory</font> approval of our products;             o        manage our growth,  control  <font color="blue">expenditures</font> and align costs with                    revenues;             o        attract, retain and motivate <font color="blue">qualified personnel</font>; and             o        respond to <font color="blue">competitive</font> <font color="blue"><font color="blue">development</font>s</font></td>
    </tr>
    <tr>
      <td>If we do not  <font color="blue"><font color="blue">effective</font>ly</font>  address  the risks we face,  our  business  model may  become   unworkable  and  we  may  not  achieve  or  sustain   <font color="blue">profitability</font>  or  <font color="blue">successfully</font> develop any products</td>
    </tr>
    <tr>
      <td>WE HAVE NOT BEEN PROFITABLE AND EXPECT FUTURE LOSSES             To date, we have not <font color="blue">been profitable</font>,  and since our inception in 1990,  we have not generated any <font color="blue">significant</font>  revenues</td>
    </tr>
    <tr>
      <td>We may never be profitable or,  if we become  profitable,  we may be unable to  sustain  <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We have  sustained  losses in <font color="blue">each year since</font> our  <font color="blue">incorporation</font> in 1990</td>
    </tr>
    <tr>
      <td>We <font color="blue">incurred net</font>  losses of dlra6cmam883cmam914, dlra5cmam906cmam890, dlra6cmam514cmam217, dlra4cmam061cmam422, and dlra1cmam774cmam527 for the  years ended <font color="blue">March                                           </font>11      <PAGE>      31,  2006,  2005,  2004,  2003 and 2002,  <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>We  expect  to  realize  <font color="blue">significant</font>  losses for the <font color="blue">current year</font> of  operation  and to continue to incur  losses  until  we are  able to  generate  sufficient  revenues  to  support  our  <font color="blue">operations</font> and offset operating costs</td>
    </tr>
    <tr>
      <td>OUR RESEARCH  ACTIVITIES  ARE  CHARACTERIZED  BY INHERENT RISK AND WE MAY NOT BE  ABLE TO  SUCCESSFULLY  DEVELOP  PRODUCTS  FOR  COMMERCIAL  USE  THAT  ARE IN OUR  PIPELINE             Our research <font color="blue">activities</font> are <font color="blue">characterized by</font> the <font color="blue">inherent risk</font> that the  research  will not yield  results that will receive FDA approval or otherwise be  suitable for <font color="blue">commercial exploitation</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>31, 2006, we have <font color="blue">entered into</font>  <font color="blue"><font color="blue">agreement</font>s</font>  <font color="blue">with respect</font> to  the <font color="blue">marketing upon</font>  <font color="blue">development</font> of four drugs</td>
    </tr>
    <tr>
      <td>Each <font color="blue">agreement</font>  provides that we  are to <font color="blue">commercially</font>  develop or co-develop the product with the partner and upon  securing  by a partner or  partners  having  FDA  approval  or other  <font color="blue">regulatory</font>  approval,  if  required,  we are to  <font color="blue">manufacture</font>  the  product  and sell it to a  partner or <font color="blue">marketing partner</font> for <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>The commercial <font color="blue">development</font> of one  of the four drugs has been  completed</td>
    </tr>
    <tr>
      <td>No assurance can be given that sales, if  any, by any <font color="blue">marketing partner</font> will result in profit for Elite from the product</td>
    </tr>
    <tr>
      <td>We have <font color="blue">also entered</font>  into two  <font color="blue">additional</font>  co-<font color="blue">development</font>  <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>These products are currently in  <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>No assurance can be given that we  will be successful in developing  these  products,  and, if successful,  that an  <font color="blue">agreement</font>  can be <font color="blue">reached with</font> a marketing  partner for the sale of the products  or that any sales of the <font color="blue">products will</font> result in profit for Elite</td>
    </tr>
    <tr>
      <td>We are also developing three <font color="blue">additional</font> products on our own</td>
    </tr>
    <tr>
      <td>Two are in  pilot Phase I studies and one is in the <font color="blue">pilot <font color="blue">bioequivalence</font></font>  stage</td>
    </tr>
    <tr>
      <td><font color="blue">Additional  </font>studies  including  <font color="blue">either pivotal</font>  <font color="blue">bioequivalence</font>  or efficacy  <font color="blue">studies will</font> be  required for these products before <font color="blue">commercialization</font></td>
    </tr>
    <tr>
      <td>In  order  for any of  these  products  to be  <font color="blue"><font color="blue">commercialize</font>d</font>,  the FDA  requires  successful  <font color="blue">completion</font>  of  pivotal  <font color="blue">biostudies</font>  to file  an ANDA  and  successful  <font color="blue">completion</font> of pivotal  clinical  trials before filing <font color="blue">a NDA The FDA  </font>next  requires  successful  <font color="blue">completion</font>  of  <font color="blue">comparative</font>  studies for drug listed  products</td>
    </tr>
    <tr>
      <td>ANDAs are <font color="blue">filed with</font>  respect to generic  versions  of  existing  FDA  <font color="blue">approved products while</font> NDAs are filed <font color="blue">with respect</font> to <font color="blue">new products</font></td>
    </tr>
    <tr>
      <td>WE  COULD  EXPERIENCE   DIFFICULTY  IN  DEVELOPING  AND  INTEGRATING   STRATEGIC  ALLIANCES, CO-DEVELOPMENT OPPORTUNITIES AND OTHER RELATIONSHIPS             With respect to products that are being developed and are available for  partnering,   we  intend  to  pursue   product-specific   licensing,   marketing  <font color="blue"><font color="blue">agreement</font>s</font>,  co-<font color="blue">development</font>  <font color="blue">opportunities</font> and other partnering  <font color="blue"><font color="blue">arrangement</font>s</font> in  <font color="blue"><font color="blue">connection</font> with</font> the products</td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into</font> partnership  <font color="blue"><font color="blue">arrangement</font>s</font> as  to six  products  but no  assurance  can be given that we will be able to locate  partners for our other products or that any  <font color="blue">arrangement</font> is or will be suitable</td>
    </tr>
    <tr>
      <td>In addition,  assuming we identify <font color="blue">suitable partners</font>, the process of <font color="blue"><font color="blue">effective</font>ly</font>  entering  into these  <font color="blue"><font color="blue">arrangement</font>s</font>  involves  risks  such that our  managementapstas  attention  may be diverted  from other  business  concerns  and that we may have  <font color="blue"><font color="blue">difficult</font>y integrating</font> the new <font color="blue"><font color="blue">arrangement</font>s</font> into our existing business</td>
    </tr>
    <tr>
      <td>OUR LIMITED EXPERIENCE IN CONDUCTING CLINICAL TRIALS AND SUBMITTING NDAS AND THE  UNCERTAINTIES  INHERENT IN  CLINICAL  TRIALS  COULD  RESULT IN DELAYS IN PRODUCT  DEVELOPMENT AND COMMERCIALIZATION             Prior to seeking FDA  approval for the  commercial  sale of any drug we  develop,   which  does  not  qualify  for  the  FDAapstas  <font color="blue">abbreviated</font>   <font color="blue">application</font>  procedures,  we or our <font color="blue">partner must</font>  <font color="blue">demonstrate</font>  through                                           12      <PAGE>      clinical  trials that these  products  are safe and  <font color="blue">effective</font>  for use</td>
    </tr>
    <tr>
      <td>We have  limited experience in conducting and <font color="blue">supervising <font color="blue"><font color="blue">clinical trial</font>s</font></font></td>
    </tr>
    <tr>
      <td>Our studies and <font color="blue">filings may</font> not result in FDA  approval to market our new drug  products  and, if the FDA grants  approval,  we  <font color="blue">cannot predict</font> the timing of any approval</td>
    </tr>
    <tr>
      <td>IF OUR CLINICAL  TRIALS ARE NOT  SUCCESSFUL  OR TAKE LONGER TO COMPLETE  THAN WE  EXPECT, WE MAY NOT BE ABLE TO DEVELOP AND COMMERCIALIZE OUR PRODUCTS             In order to obtain <font color="blue">regulatory</font>  approvals for the <font color="blue">commercial sale</font> of our  <font color="blue"><font color="blue">potential product</font>s</font>, we will be required to complete <font color="blue"><font color="blue">clinical trial</font>s</font> in humans to  <font color="blue">demonstrate</font>  the  safety and  efficacy  of the  products</td>
    </tr>
    <tr>
      <td>We may not be able to  obtain  authority  from the FDA or other  <font color="blue">regulatory</font>  agencies  to  commence  or  complete these <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>The  results  from  preclinical  testing  of a  product  that is  under  <font color="blue">development</font>  may not be  predictive  of results  that will be  obtained in human  <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>In addition, the results of early human <font color="blue"><font color="blue">clinical trial</font>s</font> may not  be  predictive of results that will be obtained in <font color="blue">larger scale</font>  advanced  stage  <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Furthermore,  we or the FDA may suspend <font color="blue"><font color="blue">clinical trial</font>s</font> at any  time  if the  subjects  <font color="blue">participating</font>  in  such  trials  are  being  exposed  to  unacceptable <font color="blue">health risks</font>, or for other reasons</td>
    </tr>
    <tr>
      <td>The rate of <font color="blue">completion</font> of <font color="blue"><font color="blue">clinical trial</font>s</font> is <font color="blue">dependent</font> in part upon the  rate of <font color="blue">enrollment</font> of subjects</td>
    </tr>
    <tr>
      <td>A favorable <font color="blue">clinical trial</font> result is a function  of many factors including the size of the subject  population,  the proximity of  subjects to  clinical  sites,  the  <font color="blue">eligibility</font>  criteria  for the study and the  existence of <font color="blue">competitive</font>  <font color="blue"><font color="blue">clinical trial</font>s</font></td>
    </tr>
    <tr>
      <td>Delays in planned subject <font color="blue">enrollment</font>  may result in increased costs and program delays</td>
    </tr>
    <tr>
      <td>We may not be able to  <font color="blue">successfully</font>  complete any  clinical  trial of a  <font color="blue"><font color="blue">potential product</font> within</font> any specified time period</td>
    </tr>
    <tr>
      <td>Moreover,  clinical  <font color="blue">trials may</font> not show any  <font color="blue">potential product</font> to be safe or <font color="blue">efficacious</font></td>
    </tr>
    <tr>
      <td>Thus, the FDA and other <font color="blue">regulatory</font>  <font color="blue">authorities may</font> not approve any of our <font color="blue"><font color="blue">potential product</font>s</font> for any <font color="blue">indication</font></td>
    </tr>
    <tr>
      <td>Our  business,  financial  condition,  or  results of  <font color="blue">operations</font>  could be  <font color="blue"><font color="blue">materially</font> <font color="blue">adversely</font> affected</font> if:             o        we are  unable  to  complete  a  clinical  trial of one of our                    <font color="blue"><font color="blue">potential product</font>s</font>;             o        the results of any <font color="blue">clinical trial</font> are unfavorable; or             o        the  time  or  cost  of  completing   the  trial  exceeds  our                    <font color="blue">expectations</font></td>
    </tr>
    <tr>
      <td>WE ARE DEPENDENT ON A SMALL NUMBER OF SUPPLIERS FOR OUR RAW  MATERIALS,  AND ANY  DELAY OR  UNAVAILABILITY  OF RAW MATERIALS CAN MATERIALLY  ADVERSELY  AFFECT OUR  ABILITY TO PRODUCE PRODUCTS             The  FDA  requires   <font color="blue">identification</font>   of  raw  material   suppliers  in  <font color="blue">application</font>s  for approval of <font color="blue">drug products</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">raw materials</font> were  unavailable  from a  specified  supplier,  FDA  approval  of a new  supplier  <font color="blue">could delay</font> the  <font color="blue">manufacture</font>  of the drug  involved</td>
    </tr>
    <tr>
      <td>In  addition,  some  materials  used in our  products are currently  available  <font color="blue">from only one supplier</font> or a limited number of  suppliers</td>
    </tr>
    <tr>
      <td>Further, a <font color="blue">significant</font> portion of our <font color="blue">raw materials</font> may be available  only from foreign  sources</td>
    </tr>
    <tr>
      <td>Foreign sources can be subject to the <font color="blue">special risks</font>  of doing business abroad, including:             o        greater  <font color="blue">possibility</font> for <font color="blue">disruption due</font> to  <font color="blue">transportation</font>  or                    <font color="blue">communication problems</font>;             o        the  relative  <font color="blue">instability</font>  of some  foreign  <font color="blue">governments</font>  and                    economies;                                           13      <PAGE>               o        <font color="blue">interim price volatility</font>  <font color="blue"><font color="blue">based on</font> labor unrest</font>,  materials or                    equipment  shortages,   export  duties,  <font color="blue">restrictions</font>  on  the                    transfer of funds, or <font color="blue">fluctuations</font> in <font color="blue">currency exchange rates</font>;                    and             o        <font color="blue">uncertainty</font>  regarding  recourse to a dependable  <font color="blue">legal system</font>                    for the <font color="blue">enforcement</font> of contracts and other rights</td>
    </tr>
    <tr>
      <td>In  addition,   recent  changes  in  patent  laws  in  certain  foreign  jurisdictions (primarily in Europe) may make it <font color="blue">increasingly <font color="blue">difficult</font></font> to obtain  raw  materials  for research and  <font color="blue">development</font>  prior to expiration of applicable  United  States or foreign  patents</td>
    </tr>
    <tr>
      <td>Any  <font color="blue">inability</font> to obtain <font color="blue">raw materials</font> on a  <font color="blue">timely basis</font>,  or any  <font color="blue">significant</font>  price  increases that cannot be passed on to  customers, could have a material adverse effect on us</td>
    </tr>
    <tr>
      <td>The delay or <font color="blue">unavailability</font>  of <font color="blue">raw materials</font> can <font color="blue">materially</font>  <font color="blue">adversely</font>  affect our ability to produce products</td>
    </tr>
    <tr>
      <td>This can <font color="blue">materially</font> <font color="blue">adversely</font> affect our  business and <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>IF THE  COMPANY  IS  UNABLE  TO  OBTAIN  ADDITIONAL  FINANCING  NEEDED  FOR  THE  EXPENDITURES  FOR THE  DEVELOPMENT AND  COMMERCIALIZATION  OF THE COMPANY &amp;apos S DRUG  PRODUCTS, IT WOULD IMPAIR THE COMPANY &amp;apos S ABILITY TO CONTINUE TO MEET ITS BUSINESS  OBJECTIVES                On March 15, 2006, the <font color="blue">Company  </font>completed a private  placement,  for  aggregate  gross  proceeds  of  dlra10cmam000cmam000,  of 10cmam000  shares of its  Series B  Preferred Stock  convertible into 4cmam444cmam444 shares of <font color="blue"><font color="blue">Common Stock</font> </font>and five year  warrants to purchase an aggregate of 2cmam222cmam222  shares of Common  Stock</td>
    </tr>
    <tr>
      <td>50prca of  <font color="blue">such warrants</font> have an exercise  price of dlra2dtta75 and 50prca have an <font color="blue">exercise price</font> of  dlra3dtta25</td>
    </tr>
    <tr>
      <td>Additionally, the placement agent received five year warrants to purchase  355cmam555 shares of <font color="blue"><font color="blue">Common Stock</font> </font>with an <font color="blue">exercise price</font> of dlra2dtta25</td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font> 31,  2006,  the  <font color="blue">Company  </font>had  aggregate  cash and cash  <font color="blue">equivalents</font>  of  <font color="blue">approximately</font>  dlra9cmam000cmam000,  which the  <font color="blue">Company  </font>anticipates  is  adequate to finance its <font color="blue">operations</font> through the next 12 to 18 months</td>
    </tr>
    <tr>
      <td>Thereafter,  the Company will require <font color="blue">additional</font> financing to insure that the Company will be  able to meet the  <font color="blue">expenditures</font>  to develop and  <font color="blue">commercialize</font>  its  products for  which  <font color="blue">requirement</font>  the  <font color="blue">Company  </font>has no current  <font color="blue"><font color="blue">arrangement</font>s</font></td>
    </tr>
    <tr>
      <td>Other  possible  sources  of the  required  financing  are the cash  exercise  of the  Long  Term  Warrants issued in the October 2004 private placement,  the <font color="blue">Replacement Warrants  </font>issued in the <font color="blue">December  </font>2005 private  placement  and other  warrants and options  that are currently  outstanding</td>
    </tr>
    <tr>
      <td>No <font color="blue">representation</font> can be made that the <font color="blue">Company  </font>will  be  able to  obtain  <font color="blue">additional</font>  financing  or if  obtained  it will be on  favorable  terms,  or at all</td>
    </tr>
    <tr>
      <td>No  assurance  can be given that any  offering if  <font color="blue">undertaken will</font> be <font color="blue">successfully</font> concluded or that if concluded the <font color="blue">proceeds will</font>  be material</td>
    </tr>
    <tr>
      <td>The Companyapstas <font color="blue">inability</font> to obtain <font color="blue">additional</font> financing when needed  <font color="blue">would impair</font> its ability to continue its business</td>
    </tr>
    <tr>
      <td>On the  other hand, if the <font color="blue">Company  </font><font color="blue">incurred debt</font>, the Company would be subject to risks  associated  with  <font color="blue">indebtedness</font>,  including  the risk that  interest  <font color="blue">rates might</font>  fluctuate and <font color="blue">cash flow would</font> be  insufficient  to <font color="blue">pay principal</font> and <font color="blue">interest on</font>  such <font color="blue">indebtedness</font></td>
    </tr>
    <tr>
      <td>IF WE ARE UNABLE TO PROTECT OUR  INTELLECTUAL  PROPERTY  RIGHTS AND AVOID CLAIMS  THAT WE INFRINGED ON THE INTELLECTUAL  PROPERTY RIGHTS OF OTHERS, OUR ABILITY TO  CONDUCT BUSINESS MAY BE IMPAIRED             Our success,  <font color="blue">competitive</font> position and amount of revenues,  <font color="blue">principally</font>  royalty  income,  if any,  will depend in part on our  ability to obtain  patent  protection in <font color="blue">various jurisdictions</font>  related to our <font color="blue">technologies</font>,  processes and  products</td>
    </tr>
    <tr>
      <td>We intend to file patent <font color="blue">application</font>s seeking such protection,  but                                           14      <PAGE>      we cannot be certain  that these  <font color="blue">application</font>s  will  result in the  issuance of  patents</td>
    </tr>
    <tr>
      <td>If patents are issued,  third  parties  <font color="blue">may sue us</font> to  challenge  such  <font color="blue">patent protection</font>, and although we know of no reason why they <font color="blue">should prevail</font>, it  is possible  that they could</td>
    </tr>
    <tr>
      <td>It is likewise  possible that our <font color="blue">patents may</font> not  prevent  third  parties  from  developing  similar  or  competing  products</td>
    </tr>
    <tr>
      <td>In  addition,  although  we are not aware of any  threatened  or pending  actions by  <font color="blue">third parties</font>  asserting that we have  <font color="blue">infringed on</font> their  patents,  and are not  aware of any  actions  we have  taken  that  would  lead to such a claim,  it is  possible that we might be sued for  <font color="blue">infringement</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">cost involved</font> in bringing  suits against others for <font color="blue">infringement</font> of our patents,  or in defending any suits  <font color="blue">brought against us</font>, can be substantial</td>
    </tr>
    <tr>
      <td>We may not possess  <font color="blue">sufficient funds</font> to  prosecute  or <font color="blue">defend such suits</font></td>
    </tr>
    <tr>
      <td>If our  products  were found to infringe  upon  <font color="blue">patents issued</font> to others,  we would be <font color="blue">prohibited from</font>  <font color="blue">manufacturing</font> or selling  <font color="blue">such products</font> and we could be required to pay substantial damages</td>
    </tr>
    <tr>
      <td>In addition,  we may be required to obtain licenses to patents or other  <font color="blue">proprietary</font>  rights of <font color="blue">third parties</font> in <font color="blue">connection</font>  with the <font color="blue">development</font> and use  of our products and <font color="blue">technologies</font> as they relate to other persons &amp;apos   <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>The  failure to obtain the  <font color="blue">necessary</font>  licenses  or other  rights  could  preclude the sale, <font color="blue">manufacture</font> or <font color="blue">distribution</font> of our products</td>
    </tr>
    <tr>
      <td>We <font color="blue">also rely upon <font color="blue">trade secrets</font></font> and  <font color="blue">proprietary</font>  know-how</td>
    </tr>
    <tr>
      <td>We seek to  protect this know-how in part by  <font color="blue"><font color="blue">confidential</font>ity</font>  <font color="blue"><font color="blue">agreement</font>s</font></td>
    </tr>
    <tr>
      <td>We  <font color="blue">consistently</font>  require our employees and potential business partners to execute <font color="blue"><font color="blue">confidential</font>ity</font>  <font color="blue"><font color="blue">agreement</font>s</font>  prior to doing  business  with us</td>
    </tr>
    <tr>
      <td>However,  it is possible that an  employee  would  disclose  <font color="blue">confidential</font>  information  in violation of his or her  <font color="blue">agreement</font>,  or that  our  trade  secrets  would  otherwise  become  known  or be  in<font color="blue">dependent</font>ly  developed  in  such a  manner  that we  will  have  no  practical  recourse</td>
    </tr>
    <tr>
      <td>We are not  engaged in any  <font color="blue">litigation</font>,  nor  contemplating  any,  with  regard to a claim that someone has <font color="blue">infringed on</font>e of our patents, revealed any of  our <font color="blue">trade secrets</font>, or <font color="blue">otherwise misused</font> our <font color="blue">confidential</font> information</td>
    </tr>
    <tr>
      <td>THE  PHARMACEUTICAL  INDUSTRY IS SUBJECT TO EXTENSIVE FDA REGULATION AND FOREIGN  REGULATION, WHICH PRESENTS NUMEROUS RISKS TO US             The  <font color="blue">manufacturing</font>  and  marketing  of  <font color="blue">pharmaceutical</font>  products in the  <font color="blue">United States </font>and abroad are subject to stringent <font color="blue">governmental</font>  regulation</td>
    </tr>
    <tr>
      <td>The  sale of any of our products for use in humans in the United  States will require  the approval of the <font color="blue">FDA Similar  </font><font color="blue">approvals by comparable</font>  agencies are required  in <font color="blue">most foreign</font>  countries</td>
    </tr>
    <tr>
      <td>The FDA has  established  <font color="blue">mandatory</font>  procedures and  <font color="blue">safety standards</font> that apply to the clinical  testing,  <font color="blue">manufacture</font> and marketing  of <font color="blue">pharmaceutical</font> products</td>
    </tr>
    <tr>
      <td><font color="blue">Obtaining FDA </font>approval for a <font color="blue">new therapeutic product</font>  may take <font color="blue">several years</font> and involve substantial <font color="blue">expenditures</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">eight products</font>  currently under <font color="blue">development</font> have not <font color="blue">yet been approved</font> for sale or use in humans  in the <font color="blue">United States </font>or elsewhere</td>
    </tr>
    <tr>
      <td>If  we  or  our  licensees   fail  to  obtain  or  maintain   requisite  <font color="blue">governmental</font>  approvals  or fail to obtain or  maintain  approvals  of the scope  requested,  it will delay or <font color="blue">preclude us</font> or our licensees or marketing  partners  from  marketing  our  products</td>
    </tr>
    <tr>
      <td>It <font color="blue">could also limit</font> the  commercial  use of our  products</td>
    </tr>
    <tr>
      <td>15      <PAGE>      THE  PHARMACEUTICAL  INDUSTRY  IS HIGHLY  COMPETITIVE  AND  SUBJECT TO RAPID AND  SIGNIFICANT  TECHNOLOGICAL  CHANGE,  WHICH COULD IMPAIR OUR ABILITY TO IMPLEMENT  OUR BUSINESS MODEL             The <font color="blue">pharmaceutical</font> industry is highly <font color="blue">competitive</font>, and we may be unable  to compete  <font color="blue"><font color="blue">effective</font>ly</font></td>
    </tr>
    <tr>
      <td>In addition,  it is undergoing  rapid and  <font color="blue">significant</font>  <font color="blue">technological</font>  change,  and we expect  <font color="blue">competition</font>  to  intensify  as  technical  advances  in <font color="blue">each field</font> are made and become  more widely  known</td>
    </tr>
    <tr>
      <td>An  increasing  number of <font color="blue">pharmaceutical</font>  companies have been or are becoming  interested in the  <font color="blue">development</font> and  <font color="blue">commercialization</font> of products  <font color="blue">incorporating</font>  advanced or novel  <font color="blue"><font color="blue">drug delivery</font> systems</font></td>
    </tr>
    <tr>
      <td>We expect that <font color="blue">competition</font> in the field of <font color="blue">drug delivery</font>  will  increase  in the  future as other  specialized  research  and  <font color="blue">development</font>  <font color="blue">companies begin</font> to <font color="blue">concentrate on</font> this aspect of the business</td>
    </tr>
    <tr>
      <td>Some of the major  <font color="blue">pharmaceutical</font>  companies have invested and are continuing to invest <font color="blue">significant</font>  resources in the <font color="blue">development</font> of their own <font color="blue"><font color="blue">drug delivery</font> systems</font> and <font color="blue">technologies</font>  and some have <font color="blue">invested funds</font> in such specialized <font color="blue">drug delivery</font>  companies</td>
    </tr>
    <tr>
      <td>Many  of our  <font color="blue">competitors</font>  have longer  operating  histories  and  greater  financial,  research  and  <font color="blue">development</font>,  marketing  and  other  resources  than we do</td>
    </tr>
    <tr>
      <td>Such  <font color="blue">companies may</font> develop new  <font color="blue">formulations</font>  and products,  or <font color="blue">may improve</font>  existing  ones, more <font color="blue">efficiently than</font> we can</td>
    </tr>
    <tr>
      <td>Our success,  if any, will depend in part on  our ability to keep pace with the changing  <font color="blue">technology</font> in the fields in which we  operate</td>
    </tr>
    <tr>
      <td>IF KEY  PERSONNEL  WERE TO LEAVE ELITE OR IF WE ARE  UNSUCCESSFUL  IN ATTRACTING  QUALIFIED PERSONNEL, OUR ABILITY TO DEVELOP PRODUCTS COULD BE MATERIALLY HARMED             Our success  depends in large part on our ability to attract and retain  highly qualified scientific, technical and business personnel experienced in the  <font color="blue">development</font>,  <font color="blue">manufacture</font>  and  marketing of  controlled  <font color="blue">release drug</font>  delivery  systems and  products</td>
    </tr>
    <tr>
      <td>Our business and  financial  results could be <font color="blue">materially</font>  <font color="blue">harmed by</font> the <font color="blue">inability</font> to attract or retain <font color="blue">qualified personnel</font></td>
    </tr>
    <tr>
      <td>IF WE WERE  SUED ON A  PRODUCT  LIABILITY  CLAIM,  AN  AWARD  COULD  EXCEED  OUR  INSURANCE COVERAGE AND COST US SIGNIFICANTLY             The design,  <font color="blue">development</font>  and  <font color="blue">manufacture</font>  of our products  involve an  <font color="blue">inherent risk</font> of product  <font color="blue">liability</font>  claims</td>
    </tr>
    <tr>
      <td>We have procured product <font color="blue">liability</font>  insurance  having a <font color="blue">maximum limit</font> of  dlra5cmam000cmam000;  however,  a successful  claim  against  us in  excess  of the  policy  limits  could be very  expensive  to us,  damaging our <font color="blue">financial position</font></td>
    </tr>
    <tr>
      <td>The amount of our insurance coverage, which has  been limited due to our limited financial resources, may be <font color="blue">materially</font> below the  coverage   maintained  by  many  of  the  other  companies  engaged  in  similar  <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>To the best of our knowledge,  no product  <font color="blue">liability</font> claim has been  made against us as of March 31, 2006</td>
    </tr>
    <tr>
      <td>OUR STOCK PRICE HAS BEEN VOLATILE AND MAY FLUCTUATE IN THE FUTURE             There has been <font color="blue">significant</font> volatility in the <font color="blue"><font color="blue">market price</font>s</font> for publicly  <font color="blue">traded shares</font> of <font color="blue">pharmaceutical</font> companies, including ours</td>
    </tr>
    <tr>
      <td>For the twelve months  ended March 31, 2006,  the closing <font color="blue">sale price on</font> the American  Stock Exchange of  our <font color="blue"><font color="blue">Common Stock</font> </font><font color="blue">fluctuated from</font> a high of dlra4dtta42 per share to a low of dlra1dtta68 per  share</td>
    </tr>
    <tr>
      <td>The per share  price of our  Common  Stock  may not  <font color="blue">remain at</font> or exceed  current  levels</td>
    </tr>
    <tr>
      <td>The market  price for our Common  Stock,  and for the stock of  <font color="blue">pharmaceutical</font>  <font color="blue">companies <font color="blue">generally</font></font>,  has <font color="blue">been highly volatile</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">market price</font>  of our <font color="blue"><font color="blue">Common Stock</font> </font>may be <font color="blue">affected by</font>:             o        Results of our <font color="blue"><font color="blue">clinical trial</font>s</font>;             o        Approval or <font color="blue">disapproval</font> of <font color="blue">abbreviated</font>  new drug  <font color="blue">application</font>s                    or new drug <font color="blue">application</font>s;             o        <font color="blue">Announcements  </font>of <font color="blue">innovations</font>,  <font color="blue">new products</font> or new patents by                    us or by our <font color="blue">competitors</font>;                                           16      <PAGE>               o        <font color="blue">Governmental </font>regulation;             o        Patent or <font color="blue">proprietary</font> rights <font color="blue"><font color="blue">development</font>s</font>;             o        Proxy contests or <font color="blue">litigation</font>;             o        News  regarding the efficacy of, safety of or demand for drugs                    or drug <font color="blue">technologies</font>;             o        Economic and market  <font color="blue">conditions</font>,  <font color="blue">generally</font> and related to the                    <font color="blue">pharmaceutical</font> industry;             o        Healthcare <font color="blue">legislation</font>;             o        Changes in third-party <font color="blue">reimbursement</font> policies for drugs; and             o        <font color="blue">Fluctuations </font>in our operating results</td>
    </tr>
    <tr>
      <td>As of this date sales of  substantial  amounts of the <font color="blue"><font color="blue">Common Stock</font> </font>in the public  market  are  eligible  for  sale by  these  holders  pursuant  to  exemption  or  <font color="blue">registration</font>  under the <font color="blue">Securities Act</font></td>
    </tr>
    <tr>
      <td><font color="blue">Perceptions </font>that substantial  sales may  take place in the <font color="blue">future may lower</font> the <font color="blue">Common Stock</font>apstas <font color="blue">market price</font></td>
    </tr>
    <tr>
      <td>THE FAILURE TO MAINTAIN THE AMERICAN STOCK EXCHANGE  LISTING OF THE COMMON STOCK  WOULD HAVE A MATERIAL  ADVERSE EFFECT ON THE MARKET FOR THE COMMON STOCK AND ITS  MARKET PRICE             On January 4, 2006,  the <font color="blue">Company  </font>received a letter  from the  American  Stock  Exchange  ( &amp;quote AMEX &amp;quote )  notifying it that,  <font color="blue">based on</font> the Companyapstas  unaudited  financial  <font color="blue">statements as</font> of <font color="blue">September </font>30, 2005, the Company is not in compliance  with the <font color="blue"><font color="blue"><font color="blue">continued listing</font> standards</font> set forth</font> in the <font color="blue">AMEX Company Guide </font>in that  under one listing standard its <font color="blue"><font color="blue">shareholder</font>s</font> &amp;apos   equity is less than dlra4cmam000cmam000 and  it had losses from continuing  <font color="blue">operations</font> and/or net losses in three of its four  most recent fiscal years and under another  listing  standard its  <font color="blue"><font color="blue">shareholder</font>s</font> &amp;apos   equity is less than  dlra6cmam000cmam000  and it had losses  from  continuing  <font color="blue">operations</font>  and/or net losses in its five most recent  fiscal  years</td>
    </tr>
    <tr>
      <td>The  Company,  at the  request of AMEX,  submitted a plan on <font color="blue">February </font>3, 2006  advising AMEX of action,  it has  taken,  and will  take,  to bring it in  compliance  with the  continued  listing  standards  within a maximum of 18 months from January 4, 2006</td>
    </tr>
    <tr>
      <td><font color="blue">On March  </font>15, 2006,  the <font color="blue">Company  </font>completed a private  placement of its Series B Preferred  Stock and warrants to purchase <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>received dlra10cmam000cmam000 in  gross  proceeds  from the  private  placement</td>
    </tr>
    <tr>
      <td>On March 21,  2006,  the <font color="blue">Company  </font>submitted an update to the plan it had <font color="blue">previously submitted on</font> <font color="blue">February </font>6, 2006</td>
    </tr>
    <tr>
      <td>Upon notice of the recent  private  placement and the  <font color="blue">acceptance</font> of the updated  plan,  AMEX provided the Company with an extension  until July 3, 2007 to regain  <font color="blue">compliance with</font> the <font color="blue"><font color="blue">continued listing</font> standards</font></td>
    </tr>
    <tr>
      <td>AMEX will allow the Company to  maintain its AMEX <font color="blue">listing through</font> the plan period, subject to <font color="blue">periodic review</font> of  the  Companyapstas  progress by the AMEX staff</td>
    </tr>
    <tr>
      <td><font color="blue">If the Company </font>is not in compliance  with the <font color="blue">continued listing</font>  standards or does not make progress  <font color="blue">consistent with</font>  such plan during the plan period, AMEX <font color="blue">may then initiate delisting</font>  <font color="blue">proceedings</font></td>
    </tr>
    <tr>
      <td>The failure to maintain listing of the <font color="blue"><font color="blue">Common Stock</font> </font>on AMEX will have an adverse  effect on the market and the <font color="blue">market price</font> for the <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>THE ISSUANCE OF  ADDITIONAL  SHARES OF OUR COMMON STOCK OR OUR  PREFERRED  STOCK  COULD MAKE A CHANGE OF CONTROL MORE DIFFICULT TO ACHIEVE             The issuance of <font color="blue">additional</font>  shares of the Companyapstas <font color="blue"><font color="blue">Common Stock</font> </font>or the  issuance of shares of an <font color="blue">additional</font>  series of Preferred  Stock could be used to  make a change of control of the <font color="blue">Company  </font>more  <font color="blue">difficult</font>  and  expensive</td>
    </tr>
    <tr>
      <td>Under  certain  <font color="blue">circumstances</font>,  <font color="blue">such shares could</font> be used to create  <font color="blue">impediments</font>  to or  <font color="blue">frustrate persons seeking</font> to cause a takeover or to <font color="blue">gain control</font> of the Company</td>
    </tr>
    <tr>
      <td>Such  shares  could be sold to  purchasers  who  might  side  with the  Board in  opposing  a  takeover  bid  that  the  Board  determines  not to be in the  best  interests of its <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>It <font color="blue">might also</font> have the effect of <font color="blue">discouraging</font> an  <font color="blue">attempt by</font> another  person or entity  through the  <font color="blue">acquisition</font>  of a substantial  number of shares of the Companyapstas <font color="blue"><font color="blue">Common Stock</font> </font>to acquire control of the <font color="blue">Company  </font>with a view to  <font color="blue">consummating</font>  a  merger,  sale  of all or                                           17      <PAGE>      part of the Companyapstas  assets, or a similar  <font color="blue">transaction</font>,  since the issuance of  <font color="blue">new shares could</font> be used to dilute the <font color="blue">stock ownership</font> of such person or entity</td>
    </tr>
    <tr>
      <td>IF PENNY  STOCK  REGULATIONS  BECOME  APPLICABLE  TO OUR COMMON  STOCK THEY WILL  IMPOSE  RESTRICTIONS ON THE MARKETABILITY OF OUR COMMON STOCK AND THE ABILITY OF  OUR STOCKHOLDERS TO SELL SHARES OF OUR STOCK COULD BE IMPAIRED             The SEC has adopted  <font color="blue">regulations</font>  that <font color="blue">generally</font> define a  &amp;quote <font color="blue">penny stock</font> &amp;quote   to be an <font color="blue">equity security</font> that has a <font color="blue">market price</font> of less than dlra5dtta00 per share or  an exercise  price of less than dlra5dtta00 per share  subject to certain  <font color="blue">exceptions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Exceptions  </font>include  equity  securities  issued  by an  issuer  that has (i) net  tangible  assets of at least  dlra2cmam000cmam000,  if <font color="blue">such issuer</font> has been in <font color="blue">continuous</font>  operation  for more <font color="blue">than three years</font>,  or (ii) net  tangible  assets of at least  dlra5cmam000cmam000,  if <font color="blue">such issuer</font> has been in <font color="blue">continuous</font> operation for <font color="blue">less than three</font>  years, or (iii) average  revenue of at least  dlra6cmam000cmam000 for the <font color="blue">preceding three</font>  years</td>
    </tr>
    <tr>
      <td>Unless an exception is available,  the <font color="blue">regulations</font> require that prior to  any <font color="blue">transaction</font>  involving a <font color="blue">penny stock</font>, a risk of <font color="blue">disclosure</font>  schedule must be  delivered  to the buyer  explaining  the <font color="blue">penny stock</font>  market and its risks</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we  <font color="blue">currently fall under one</font> of the  <font color="blue">exceptions</font>,  if at a later time we fail to meet  one of the  <font color="blue">exceptions</font>,  our <font color="blue"><font color="blue">Common Stock</font> </font>will be  considered a <font color="blue">penny stock</font></td>
    </tr>
    <tr>
      <td>As  such the <font color="blue">market liquidity</font> for our <font color="blue"><font color="blue">Common Stock</font> </font>will be limited to the ability of  broker-dealers  to sell it in  compliance  with the  above-mentioned  <font color="blue">disclosure</font>  <font color="blue">requirement</font>s</td>
    </tr>
    <tr>
      <td>You should be aware that,  <font color="blue">according</font>  to the SEC,  the market for penny  stocks has  suffered  in recent  years from  patterns  of fraud and abuse</td>
    </tr>
    <tr>
      <td>Such  patterns include:             o        <font color="blue">Control  </font>of  the  market  for  the  security  by  one or a few                    broker-dealers;             o         &amp;quote Boiler room &amp;quote  practices involving high-pressure sales tactics;             o        <font color="blue">Manipulation  </font>of  prices  through   prearranged   matching  of                    purchases and sales;             o        The release of misleading information;             o        <font color="blue">Excessive </font>and undisclosed bid-ask <font color="blue">differentials</font> and markups by                    selling broker-dealers; and             o        Dumping of securities by broker-dealers after prices have been                    <font color="blue">manipulated</font> to a desired  level,  <font color="blue">which hurts</font> the price of the                    stock and causes investors to <font color="blue">suffer loss</font></td>
    </tr>
    <tr>
      <td>We are aware of the abuses that have  occurred  in the <font color="blue">penny stock</font>  market</td>
    </tr>
    <tr>
      <td><font color="blue">Although  </font>we do not expect to be in a position  to dictate  the  behavior of the  market or of broker-dealers who <font color="blue">participate</font> in the market, we <font color="blue">will strive within</font>  the confines of <font color="blue">practical limitations</font> to prevent such abuses <font color="blue">with respect</font> to our  <font color="blue">Common Stock</font></td>
    </tr>
    <tr>
      <td>SECTION 203 OF THE DELAWARE GENERAL CORPORATION LAW MAY DETER A THIRD PARTY FROM  ACQUIRING US             Section 203 of the Delaware General  Corporation Law prohibits a merger  with a 15prca <font color="blue">shareholder</font> within three years of the <font color="blue">date such <font color="blue">shareholder</font></font>  acquired  15prca, unless the <font color="blue">merger meets one</font> of several <font color="blue">exceptions</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">exceptions</font> include,  for example,  <font color="blue">approval by</font> the holders of  two-thirds of the  outstanding  shares  (not  counting the 15prca  <font color="blue">shareholder</font>),  or <font color="blue">approval by</font> the Board prior to the 15prca  <font color="blue">shareholder</font> acquiring its 15prca ownership</td>
    </tr>
    <tr>
      <td>This provision makes it <font color="blue">difficult</font> for a  <font color="blue">potential acquirer</font> to force a <font color="blue">merger with</font> or takeover of the Company,  and could  thus  limit the price  that  certain  investors  might be  willing to pay in the  future for shares of our <font color="blue">Common Stock</font></td>
    </tr>
  </tbody>
</table>